open access

Vol 9, No 6 (2008): Practical Diabetology
Review articles (submitted)
Published online: 2008-12-22
Get Citation

Management of diabetic dyslipidemia - what is new?

Longina Kłosiewicz-Latoszek
Diabetologia Praktyczna 2008;9(6):251-258.

open access

Vol 9, No 6 (2008): Practical Diabetology
Review articles (submitted)
Published online: 2008-12-22

Abstract

Patients with diabetes mellitus or metabolic syndrome frequently have higher triglicerides, lower HDL cholesterol and more small dense LDL particles, and this combination contributes significantly to their cardiovascular risk. In addition to diet and exercise, statins remain the primary drugs of choice in patients with diabetic dyslipidemia. However statin therapy alone is often insufficient for managing cardiovascular diseases (CVD) and achieving target goals. Despite low LDL levels, the residual CVD risk for many patients is elevated. Low HDL cholesterol levels and high trigliceryde levels are important contributors to residual risk. For these patients combination lipid- modifying therapy may be recommended. Statin plus fibrate or niacin or omega-3 fatty acids may be considered. Combined lipid-lowering therapy could be anticipated to offer additional clinical benefits in patients with dyslipidemia. Data from prospective randomised trials are needed to evaluate the outcome benefits and tolerability of this kind of therapy.

Abstract

Patients with diabetes mellitus or metabolic syndrome frequently have higher triglicerides, lower HDL cholesterol and more small dense LDL particles, and this combination contributes significantly to their cardiovascular risk. In addition to diet and exercise, statins remain the primary drugs of choice in patients with diabetic dyslipidemia. However statin therapy alone is often insufficient for managing cardiovascular diseases (CVD) and achieving target goals. Despite low LDL levels, the residual CVD risk for many patients is elevated. Low HDL cholesterol levels and high trigliceryde levels are important contributors to residual risk. For these patients combination lipid- modifying therapy may be recommended. Statin plus fibrate or niacin or omega-3 fatty acids may be considered. Combined lipid-lowering therapy could be anticipated to offer additional clinical benefits in patients with dyslipidemia. Data from prospective randomised trials are needed to evaluate the outcome benefits and tolerability of this kind of therapy.
Get Citation

Keywords

atherogenic dyslipidemia; residual risk of CVD; statins; fibrates; niacin; omega-3; combined lipid therapy

About this article
Title

Management of diabetic dyslipidemia - what is new?

Journal

Clinical Diabetology

Issue

Vol 9, No 6 (2008): Practical Diabetology

Pages

251-258

Published online

2008-12-22

Bibliographic record

Diabetologia Praktyczna 2008;9(6):251-258.

Keywords

atherogenic dyslipidemia
residual risk of CVD
statins
fibrates
niacin
omega-3
combined lipid therapy

Authors

Longina Kłosiewicz-Latoszek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl